The approved vaccines target the S protein because this is the one that binds to the ACE2 (angiotensin-converting enzyme 2) receptor; thus, developing a humoral immune response against it could generate the formation of neutralizing antibodies to prevent infection. Here, PROS1 is linked to infection.